阿巴卡韦/拉米夫定联合治疗 HIV：综述。
Abacavir/lamivudine combination in the treatment of HIV: a review.
机构信息
Division of Infectious Diseases, Wayne State University, Detroit, MI, USA;
出版信息
Ther Clin Risk Manag. 2010 Mar 3;6:83-94. doi: 10.2147/tcrm.s1657.
Abacavir has been at the center of research and clinical interest in the last two years. The frequency of the associated abacavir hypersensitivity syndrome has decreased substantially since the introduction of routine testing for the HLA-B*5701 allele; the activity of the drug in HIV-infected persons with HIV RNA values more than 100,000 copies/mL has been questioned; the possible increased risk of myocardial infarction after recent exposure to abacavir has been debated; and the drug has been moved from the "recommended" category to the "alternative" category in several guidelines. Still, the drug remains a useful agent in combination with other drugs, including lamivudine, for the treatment of HIV infection. This review will focus on the pharmacokinetics, activity, side effects, and resistance profile of both abacavir and lamivudine, including a thorough review of all of the recent studies relevant to both drugs.
在过去的两年中，阿巴卡韦一直是研究和临床关注的焦点。自从常规检测 HLA-B*5701 等位基因以来，与阿巴卡韦相关的超敏反应综合征的频率已大大降低；该药物在 HIV RNA 值超过 100000 拷贝/mL 的 HIV 感染者中的活性受到质疑；最近接触阿巴卡韦后可能增加心肌梗死的风险受到争议；并且该药物已在几项指南中从“推荐”类别移至“替代”类别。尽管如此，该药仍然是与其他药物（包括拉米夫定）联合治疗 HIV 感染的有效药物。这篇综述将重点介绍阿巴卡韦和拉米夫定的药代动力学、活性、副作用和耐药谱，包括对这两种药物的所有最新研究的全面回顾。
Zotero 插件